P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 9.7 SEK -1.02% Market Closed
Market Cap: 49.9m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Intrinsic Value

PROGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one PROGEN stock under the Base Case scenario is 6.83 SEK. Compared to the current market price of 9.7 SEK, Prostatype Genomics AB is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PROGEN Intrinsic Value
6.83 SEK
Overvaluation 30%
Intrinsic Value
Price
P
Worst Case
Base Case
Best Case

Valuation Backtest
Prostatype Genomics AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PROGEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PROGEN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Prostatype Genomics AB

Provide an overview of the primary business activities
of Prostatype Genomics AB.

What unique competitive advantages
does Prostatype Genomics AB hold over its rivals?

What risks and challenges
does Prostatype Genomics AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Prostatype Genomics AB.

Provide P/S
for Prostatype Genomics AB.

Provide P/E
for Prostatype Genomics AB.

Provide P/OCF
for Prostatype Genomics AB.

Provide P/FCFE
for Prostatype Genomics AB.

Provide P/B
for Prostatype Genomics AB.

Provide EV/S
for Prostatype Genomics AB.

Provide EV/GP
for Prostatype Genomics AB.

Provide EV/EBITDA
for Prostatype Genomics AB.

Provide EV/EBIT
for Prostatype Genomics AB.

Provide EV/OCF
for Prostatype Genomics AB.

Provide EV/FCFF
for Prostatype Genomics AB.

Provide EV/IC
for Prostatype Genomics AB.

What are the Revenue projections
for Prostatype Genomics AB?

How accurate were the past Revenue estimates
for Prostatype Genomics AB?

What are the Net Income projections
for Prostatype Genomics AB?

How accurate were the past Net Income estimates
for Prostatype Genomics AB?

What are the EPS projections
for Prostatype Genomics AB?

How accurate were the past EPS estimates
for Prostatype Genomics AB?

What are the EBIT projections
for Prostatype Genomics AB?

How accurate were the past EBIT estimates
for Prostatype Genomics AB?

Compare the revenue forecasts
for Prostatype Genomics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Prostatype Genomics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Prostatype Genomics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Prostatype Genomics AB compared to its peers.

Compare the P/E ratios
of Prostatype Genomics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Prostatype Genomics AB with its peers.

Analyze the financial leverage
of Prostatype Genomics AB compared to its main competitors.

Show all profitability ratios
for Prostatype Genomics AB.

Provide ROE
for Prostatype Genomics AB.

Provide ROA
for Prostatype Genomics AB.

Provide ROIC
for Prostatype Genomics AB.

Provide ROCE
for Prostatype Genomics AB.

Provide Gross Margin
for Prostatype Genomics AB.

Provide Operating Margin
for Prostatype Genomics AB.

Provide Net Margin
for Prostatype Genomics AB.

Provide FCF Margin
for Prostatype Genomics AB.

Show all solvency ratios
for Prostatype Genomics AB.

Provide D/E Ratio
for Prostatype Genomics AB.

Provide D/A Ratio
for Prostatype Genomics AB.

Provide Interest Coverage Ratio
for Prostatype Genomics AB.

Provide Altman Z-Score Ratio
for Prostatype Genomics AB.

Provide Quick Ratio
for Prostatype Genomics AB.

Provide Current Ratio
for Prostatype Genomics AB.

Provide Cash Ratio
for Prostatype Genomics AB.

What is the historical Revenue growth
over the last 5 years for Prostatype Genomics AB?

What is the historical Net Income growth
over the last 5 years for Prostatype Genomics AB?

What is the current Free Cash Flow
of Prostatype Genomics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Prostatype Genomics AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Prostatype Genomics AB

Current Assets 3.2m
Cash & Short-Term Investments 1.8m
Receivables 1.2m
Other Current Assets 200k
Non-Current Assets 29.1m
Long-Term Investments 81k
PP&E 53k
Intangibles 29m
Other Non-Current Assets -1k
Current Liabilities 19m
Other Current Liabilities 19m
Efficiency

Earnings Waterfall
Prostatype Genomics AB

Revenue
1m SEK
Cost of Revenue
3.1m SEK
Gross Profit
4.1m SEK
Operating Expenses
-42.2m SEK
Operating Income
-38.1m SEK
Other Expenses
-2.4m SEK
Net Income
-40.5m SEK

Free Cash Flow Analysis
Prostatype Genomics AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PROGEN Profitability Score
Profitability Due Diligence

Prostatype Genomics AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
24/100
Profitability
Score

Prostatype Genomics AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

PROGEN Solvency Score
Solvency Due Diligence

Prostatype Genomics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
43/100
Solvency
Score

Prostatype Genomics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PROGEN Price Targets Summary
Prostatype Genomics AB

There are no price targets for PROGEN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PROGEN?

Click here to dive deeper.

Dividends

Prostatype Genomics AB
does not pay dividends
Shareholder Yield

Current shareholder yield for PROGEN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Prostatype Genomics AB

Country

Sweden

Industry

Biotechnology

Market Cap

49.9m SEK

Dividend Yield

0%

Description

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.

Contact

STOCKHOLM
Solna
Industrivagen 19
+468208700
www.prostatypegenomics.com

IPO

2020-11-03

Employees

-

Officers

CEO & MD
Mr. Fredrik Rickman
Chief Financial Officer
Mr. Anders Koch
Vice President Commercial operations
George Skinner
Chief Technology Officer
Ms. Emelie Berglund
Communications Director
Mr. Nicklas Rosendal
Chief Auditor
Joakim Soderin
Show More
Global Chief Medical Officer
Prof. Gerald L. Andriole Jr., M.D.
President US operations
Mr. Steven Gaal
QA & RA Manager
Katarina Sjöberg
Sales Director of EMEA
Mats Bergström
Show Less

See Also

Discover More
What is the Intrinsic Value of one PROGEN stock?

The intrinsic value of one PROGEN stock under the Base Case scenario is 6.83 SEK.

Is PROGEN stock undervalued or overvalued?

Compared to the current market price of 9.7 SEK, Prostatype Genomics AB is Overvalued by 30%.

Back to Top